Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The APP divergent transcript (APP-DT) is a long non-coding RNA, meaning it does not encode a protein. It is transcribed from the *APP* locus on chromosome 21 in the direction opposite to the canonical *APP* gene. Divergent transcripts such as APP-DT are generated from promoters that yield non-coding, often unstable RNAs oriented antisense to nearby protein-coding genes[1][5][7]. There is currently limited characterization of APP-DT's function, and it is not a receptor, enzyme, or established therapeutic target. Its relevance, if any, is likely to be in gene regulation or maintaining chromatin structure, as is broadly suggested for other divergent lncRNAs, though no direct functional evidence for APP-DT exists[2][6][5].
Not applicable; there are no drugs or inhibitors known to target this transcript
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on APP divergent transcript (APP-DT).